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Background: Fatigue, slowness, apathy and decrease in level of activity are common long-term complaints after a
subarachnoid haemorrhage (SAH). They resemble the symptoms frequently found in patients with endocrine
dysfunction. Pituitary dysfunction may be the result of SAH or its complications. We therefore hypothesized that it
may explain some of the long-term complaints after SAH.
We reviewed the literature to clarify the occurrence, pattern and severity of endocrine abnormalities and we
attempted to identify risk factors for hypopituitarism after SAH. We also assessed the effect of hypopituitarism on
long-term functional recovery after SAH.
Methods: In a MEDLINE search for studies published between 1995 and 2014, we used the term subarachnoid
haemorrhage in combination with pituitary, hypopituitarism, growth hormone, gonadotropin, testosterone, cortisol
function, thyroid function and diabetes insipidus. We selected all case-series and cohort studies reporting endocrine
function at least 3 months after SAH and studied their reported prevalence, pathogenesis, risk factors, clinical course
and outcome.
Results: We identified 16 studies describing pituitary function in the long term after SAH. The reported prevalence
of endocrine dysfunction varied from 0 to 55% and the affected pituitary axes differed between studies. Due to
methodological issues no inferences on risk factors, course and outcome could be made.
Conclusions: Neuroendocrine dysfunction may be an important and modifiable determinant of poor functional
outcome after SAH. There is an urgent need for well-designed prospective studies to more precisely assess its
incidence, clinical course and effect on mood, behaviour and quality of life.
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Subarachnoid haemorrhage (SAH) accounts for 5% of
stroke deaths and for more than a quarter of potential life
years lost by stroke. The incidence of SAH in Western
Europe is 10.5 per 100.000 persons per year and varies be-
tween regions. Case fatality ranges between 32 and 67% and
about a third of patients remain dependent [1,2]. The cause
of SAH is a ruptured aneurysm in 85%, perimesencephalic
haemorrhage in 10%, and rare conditions in 5% of the cases
[3]. Even after a good neurological recovery, a considerable
proportion of patients have symptoms interfering with daily* Correspondence: l.khajeh@erasmusmc.nl
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reproduction in any medium, provided the orlife. Fatigue, cognitive and affective dysfunction [4-7],
decrease in level of activity and social participation and
hence, quality of life, have been described in these patients
[5]. Physical disability, social-economic status, personality,
stressful events preceding SAH and life threatening illness
may each contribute to the performance state of patients
after SAH [4,8-11]. Glasgow Coma Scale (GCS), Hunt &
Hess Scale, age, cardiac history, smoking, hypertension,
new-onset seizures and mean S100B-protein levels are
some of the predictors for functional outcome after
SAH [12-16].
In recent years, associations have been made between
SAH and hypopituitarism [17,18]. In 1914, Simmonds first
described hypopituitarism as the inability of the pituitary
gland to produce sufficient hormones to meet the needs ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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itself or by an insufficient supply of hypothalamic-release-
hormones. In general, hypopituitarism is a chronic condi-
tion and remains present for life [19]. Adrenocorticotropic
(ACTH) and thyroid stimulating hormone (TSH) deficiency
may cause fatigue, weakness, headache, altered mental ac-
tivity, and impaired memory [19,20]. Growth-hormone de-
ficiency (GHD) may cause lack of vigour, fatigue, decreased
exercise tolerance and decreased social functioning [19,20].
Luteinizing hormone (LH) and follicle- stimulating hor-
mone (FSH) deficiency in women lead to oligomenorrhea,
dyspareunia, infertility and loss of libido. Testosterone
deficiency in men can present with impaired sexual func-
tioning, mood impairment, and loss of libido [19,20].
Antidiuretic hormone deficiency (ADH) leads to polyuria
and polydipsia [19-21]. Many of the long-term symptoms
after SAH show similarity to those occurring in patients
with untreated hypopituitarism. Therefore, neuroendo-
crine dysfunction may be the cause or a contributing fac-
tor for residual symptoms after SAH. If this is true,
deficient hormones can be supplied which may lead to im-
provement of these residual symptoms and improvement
of long-term outcome after SAH. Nevertheless, hypopitu-
itarism are easily overlooked after SAH and a need for
routine assessment of the pituitary axes after SAH has
been suggested [17].
The current review concerning neuroendocrine dys-
function in patients surviving SAH is aimed at assessing
its incidence, clinical manifestation and risk factors. Fur-
thermore, the effects of neuroendocrine dysfunction on
clinical symptoms and functional outcome in patients
with SAH are studied.
Methods
Search strategy
We searched Pubmed and Embase for articles published
from 1995 to 2014 and used a combination of the term
“subarachnoid haemorrhage” with “pituitary function”,
“hypopituitarism”, “growth hormone”, “thyroid function”,
“growth hormone”, “cortisol”, “gonadotropin”, “testoster-
one function” and “diabetes insipidus”. We also searched
the reference lists of the articles identified by our search
strategy. Two authors (LK, FK) screened titles and ab-
stracts of all references listed in the search results inde-
pendently. Of the remaining titles, full-text articles were
retrieved and again screened for eligibility by both au-
thors independently. In case of disagreement, consensus
was sought through discussion. A third author (DD) was
available if consensus could not be reached.
Selection criteria
A full-text article was included in this review if it met all
of the following criteria: 1) the study population consisted
of patients with SAH caused by a ruptured aneurysm or,of a subgroup of patients with aneurysmal SAH; 2) the pri-
mary aim of the study was to investigate the incidence of
endocrine dysfunction after SAH; 3) outcome was de-
scribed in terms of levels of one or a combination of the
following: ACTH, GH, TSH, cortisol, FSH, LH or testos-
terone, with a clear description of the assays; 4) time to la-
boratory investigation was at least 3 months after SAH;
and 5) the study concerned a series of patients.
Quality assessment
The two reviewers independently judged all studies by in-
ception cohort, description of source population, descrip-
tion of inclusion criteria, follow-up more than 3 months,
description loss to follow-up, standardized or valid mea-
surements and data presentation of most important out-
come measures. Items were scored as positive, negative or
inconclusive (Table 1). A completed PRISMA checklist for
quality assessment has been added as an Additional file 1.
Data presented in de studies were then collected. Informa-
tion on patient and study characteristics, inclusion and ex-
clusion criteria, laboratory and outcome measurements
were gathered from the selected articles.
Results
Selection of studies
Initially, 194 citations (abstracts) were found. Of these cita-
tions, 62 articles did not report relevant endocrine out-
come. Eighty-eight studies concerned other diseases than
aneurysmal SAH. Eighteen case reports were also excluded.
Twenty-six full-text articles were collected of which 5 arti-
cles reported only early phase endocrine dysfunction
[22-26], 3 were review articles [27-29], 1 article reported
combined data of SAH with traumatic brain injury [30]
and 1 large study was excluded because it concerned an
internet based data collection study [31]. Finally sixteen
studies fulfilled the inclusion criteria and were eligible for
the current review (Figure 1).
Study characteristics and methodological quality
Study population size ranged from 10–93 patients. Six
studies were cross-sectional or retrospective cohort stud-
ies [17,32-37]. Ten studies were conducted prospectively
[37-45]. Interval between SAH and neuroendocrine as-
sessment in studies reporting neuroendocrine outcome
ranged from 3 months to 10 years.
Dimopoulou et al. retrospectively analysed 30 patients
between one and two years after SAH but did not use a
stimulation test for the evaluation of growth hormone
function [17]. Aimaretti et al. conducted a prospective
follow-up study of 40 patients after SAH derived from
multiple Italian centres. The patients were all conscious
and measured 3 months after discharge from the ICU.
GHRH+ arginine test was used to measure growth hor-
mone function [37]. Aimaretti et al. prospectively studied
Table 1 Summary of study characteristics of studies included in this literature review
Study
design
Inclusion
criteria
Exclusion
criteria
Selection
bias
Lost to
FU nr
Dynamic tests Analysis Results
Aimaretti et al. [37] Prospective
cohort
- - yes 0 GHRH-arg + +
Brandt et al. [33] Case series + + yes 0 TRH test & ITT (7 out of 10 pts) + +
Dimopoulou et al. [17] Retrospective
cohort
+ + yes 0 none + +
Kreitschmann-Andermahr
et al. [35]
Retrospective
cohort
+ + yes 10 TRH-LHRH test & ITT + +
Aimaretti et al. [32] Prospective
cohort
- - yes 0 GHRH-arg + +
Kreitschmann- Andermahr
et al. [36]
Case series + + yes 8 ITT (14 out of 45 pts) + +
Jovanovic et al. [34] Case series + + yes 0 none + +
Tanriverdi et al. [39] Prosective
cohort
+ + no 0 GHRH-arg & glucagon test + +
Klose et al. [40] Prospective
cohort
+ + no 0 ITT (GHRH-arg if contraindicated) + +
Lammert et al. [38] Prospective
cohort
+ + yes 4 ACTH stimulation test (ITT in some
patients)
+ +
Dutta et al. [46] Retrospective
cohort
+ + yes 0 none + +
Gardner et al. [41] Prospective
cohort
+ + no 0 GHRH-arg and glucagon test + +
Khursheed et al. [43] Prospective
cohort
+ + no 0 none + +
Kronvall et al. [44] Prospective
cohort
+ + no 6 GHRH-arg no no
Karaca et al. [45] Prospective
cohort
+ + no 2 Glucagon test + +
Blijdorp et al. [42] Prospective
cohort
+ + yes 0 Ghrelin test and GHRH-arg, Synacten
test in some patients
+ +
+: inclusion criteria, exclusion criteria, assessment methods and results clearly defined and reflected, -: inclusion criteria, exclusion criteria, assessment methods
and results not or not clearly defined.
GHRH- arg test: growth hormone releasing hormone plus arginine test, ITT: insulin tolerance test, d: TRH: thyrotropin releasing hormone, ACTH:
adrenocorticotropic hormone, LHRH: gonadotropin releasing hormone, lost to FU number: number of patients lost in follow up of studies with more than one
measurement overtime.
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monal tests and GHRH+ arginine test as a dynamic test
to establish GHD between 3 and 12 months after SAH
[32]. Brandt et al. selected 10 patients with fatigue after
SAH and measured corticotrophin, growth hormone and
thyrotrophic function using insulin tolerance test (ITT)
and TSH-Thyroid releasing hormone stimulation tests12
month after SAH. In 30% of the patients ITT was not
performed [33]. Kreitschman-Andermahr et al. retrospect-
ively studied 40 SAH patients from a cohort of 274 pa-
tients after excluding patients with liver disease, coronary
heart disease, convulsions, DM, depression, severe confu-
sional state or vegetative state after discharge. ITT and
THRH-LHRH were used as dynamic tests for assessment
of ACTH, TSH and GH function 12 to 72 months after
SAH [35]. Kreitschman-Andermahr et al. retrospectively
measured basal hormones in 45 patients 3 to 24 mothsafter SAH. Only 14 patients had dynamic tests [36]. Jova-
novic et al. retrospectively evaluated endocrine function in
93 patients, between one and ten years after SAH, how-
ever stimulation tests were not used [34]. Tanriverdi et al.
prospectively analysed 22 patients one year after SAH
using basal and dynamic tests for ACTH and GHD [39].
Karaca et al. did a follow-up study, three years after SAH
of 20 patients investigated by Tanriverdi et al. in the
abovementioned study using basal hormonal tests and glu-
cagon stimulation test [45]. They found 4 cases of GHD
three years after SAH of whom three did not have GHD
one year after SAH. Dutta et al. evaluated endocrine func-
tion in 60 SAH patients with anterior communicating ar-
tery (A-com) and middle cerebral artery (MCA) aneurysms
using only basal hormonal tests. Part of the study was
retrospective, analysing patients one year after SAH and
partly prospectively analysing patients 6 months after SAH
Figure 1 Flowchart outlining the selection process of articles for review according to PRISMA guidelines. From: Moher D, Liberati A,
Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement.
PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097. For more information, visit www.prisma-statement.org.
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in the acute phase and 3 to 6 months after SAH, using
basal hormonal test and GHRH-arg test for GHD. They
did not use a dynamic test to establish ACTH deficiency
[44], Khursheed et al. prospectively analyzed 73 patients
nine months after SAH for TSH and gonadotropin defi-
ciency and not the other anterior pituitary hormones
[43]. Blijdorp et al. prospectively analysed 84 patients
and reported preliminary data of 43 patients using basal
hormonal tests, synacten test when ACTH deficiency
was suspected and a ghrelin test in the early phase after
SAH and confirmatory GHRH-arg test after six months
[42]. The most prominent methodological shortcom-
ings were the incomplete reports of patient selection
[17,32,33,35,37,46], selection bias [17,33-35,42,46] and in-
adequate laboratory testing [17,33,35,36,38,43,44]. Some
studies did not use dynamic tests to determine growth
hormone or corticotrophin deficiency [17,34,43,44,46]. In
some reports, description of the statistical analysis and re-
sults were incomplete [36] or even absent [33].
Frequency and type of hypopituitarism after SAH
In total, 671 patients were examined for hypopituitarism
after SAH (Table 2). The proportion of patients withendocrine dysfunction varied from 0 - 55%. Growth hor-
mone deficiency occurred in 0 to 29%, adrenocorticotropic
deficiency in 0 to 40%, gonadotropin (luteinizing hormone,
follicle stimulating hormone and testosterone) deficiency in
0 to 40% and thyroid stimulating hormone deficiency in 0
to 20% of patients in different studies. The largest prospect-
ive study by Klose et al. evaluated 62 patients for an average
of 14 months (range 11–26 months) after SAH. Although
they found some evidence of hypopituitarism after initial
testing, they were not able to confirm hypopituitarism by
confirmatory laboratory tests. They found no evidence of
hypopituitarism in the long term after SAH [40]. In another
well designed study, two different confirmatory tests were
used to establish GHD adjusting the outcome for body-
mass index [41]. After 12 months, 12% of the patients had
pituitary dysfunction (PD).
Predictors for hypopituitarism after SAH
Inconsistent results for predicting hypopituitarism after
SAH were reported. In a series of 93 patients with SAH,
cerebral vasospasm and hydrocephalus were identified as
risk factors for pituitary dysfunction [34]. Kreitschmann-
Andermahr et al. found a significant association of fe-
male sex and the presence of corticotrophin deficiency
Table 2 Summary of studies assessing frequency of pituitary deficiency after SAH
Study Time after SAH
(months)
Patients n GH% ACTH% TSH% LH/FSH% Testosterone% Multiple% Total%
Aimaretti et al. [37] 3 40 25 2.5 7.5 12.5 * 10 37.5
Brandt et al. [33] 12 10 10 0 20 10 30 30 30
Dimopoulou et al. [17] 12-24 30 37 10** 7*** 13 * 13 47
Kreitschmann-Andermahr et al. [35] 12-66 40 20 40 4 0 0 12 55
Aimaretti et al. [32] 12 32 21.8 6.25 9 3 3 6 37.5
Kreitschmann-Andermahr et al. [36] 3-24 45 8 13 0 0 0 9 13
Jovanovic et al. [34] 12-120 93 29 22 2.5 7.5 * 7.5 49.5
Lammert et al. [38] 6 26 0 0 4 0 0 0 4
Tanriverdi et al. [39] 12 22 36 14 0 0 0 4 50
Klose et al. [40] 12-24 62 0 0 0 0 0 0 0
Gardner et al. [41] 12 50 10 2 0 0 0 0 12
Dutta et al. [47] 6 60 15 2 13 13 23 6 31.6
Kronvall et al. [44] 3-6 45 7 18 2 4 * NR 27
Khursheed et al. [43] 9 73 NR NR 3 0 0 0 3
Karaca et al. [45] 36 20 20 0 0 0 0 0 20
Blijdorp et al. [42] 6 43 14 0 0 28 * 7 30
Abbreviations: n: numbers; %: percentage; FSH: follicle-stimulating hormone; LH: luteinizing hormone; TSH: thyroid-stimulating hormone; GH: growth hormone;
ACTH: adrenocorticotropic hormone; NR: not reported; *Reporting LH, FSH and testosterone together as gonadotropin deficient; **ACTH hypo-responsive;
***Subclinical TSH deficient.
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cantly associated with pituitary dysfunction at follow-up
[44] but Tanriverdi et al. found higher age to be associated
with growth hormone deficiency in the acute phase after
SAH [39]. These findings were not confirmed by other
studies [17,32,40,47].
Association between hypopituitarism after SAH and
functional recovery
In a series of 26 patients, 14 (54%) had neuropsychological
deficits, but only 1 patient suffered neuroendocrine dys-
function at six months after SAH [38]. A study of 40 pa-
tients evaluated the effect of neuroendocrine dysfunction
on quality of life and psychiatric symptoms. Low basal cor-
tisol level was associated with low quality of life scores
and high depression scores [48]. Severe GH deficiency was
associated with low scores on the energy subscale of
Nottingham Health Profile (NHP) questionnaire. Gardner
et al. did not find an association between PD and quality
of life after SAH, measured using the quality of life in
adult GHD assessment (QOL-AGHDA) [41].
Discussion
From the 16 studies we evaluated in this review, 15
showed some evidence for neuroendocrine dysfunction
on one or more pituitary axes in the long term after
SAH. In one study neuroendocrine dysfunction was only
present in part of the patients in the early phase and not
in the long-term after SAH. Most frequently, growthhormone deficiency was found, subsequently followed by
adrenocorticotropic deficiency, gonadotropic deficiency
and TSH deficiency. The reported prevalence of hypo-
pituitarism varied from 0 to 55%. Single hormone defi-
ciencies, mainly GHD, were more frequently found than
multiple hormone deficiencies. The axes that were af-
fected also varied among different studies.
Several mechanisms may lead to altered pituitary func-
tion in patients with SAH. Endocrine dysfunction may be
provoked by compression of the hypothalamic-pituitary
complex by the aneurysm itself, post-haemorrhagic local
tissue pressure changes, toxic effects of extravasated blood,
ischemia caused by vasospasm, increased intracranial pres-
sure, hydrocephalus, or local destruction during craniot-
omy. The pituitary gland is divided into an anterior and
posterior lobe. The anterior lobe is responsible for produ-
cing several peptide hormones: ACTH, TSH, prolactin,
GH and gonadotropin hormones: LH and FSH. The pos-
terior pituitary is a storage organ for the ADH and oxyto-
cin [19]. The pituitary gland is supplied with blood from
the branches of the internal carotid artery, which form a
capillary plexus in the region of the median eminence of
the hypothalamus. Blood from this area reaches the anter-
ior pituitary by means of long and short portal veins
through the pituitary stalk. The middle and inferior hypo-
physeal arteries supply the pituitary stalk and neurohyp-
ophysis with arterial blood [19]. This difference in blood
supply might play a role in the pathophysiology of endo-
crine dysfunction after SAH, because it is the anterior
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Nevertheless, posterior pituitary can also be affected.
Hyponatremia is a common symptom in the early phase of
SAH [49]. The exact mechanism of this complication after
SAH is still poorly understood. There are different theories
about the cause of this symptom. Different study groups
have suggested syndrome of inappropriate antidiuretic hor-
mone secretion as the main cause of hyponatremia after
SAH [50,51]. Yet others have suggested cerebral salt wast-
ing syndrome due to the rise of atrial natriuretic peptide
(ANP) and brain natriuretic peptide (BNP) together with
volume depletion through ADH hypo-secretion [52-56].
Furthermore, due to the presence of ACTH deficiency in
the early phase after SAH [25,40], ACTH deficiency has
also been mentioned as one of the possible mechanisms
for developing hyponatremia. Clinical evidence for this
theory is lacking and needs further evaluation [51]. Intri-
guingly, single deficiencies were more often described than
multiple hormonal deficiencies. This may imply that spe-
cific parts or systems of the anterior lobe of the pituitary
gland are more vulnerable to damage than others. On the
other hand, the single anterior pituitary axis deficiencies
may be a marker of multiple deficiencies, which are not de-
tected due to inappropriate testing.
The inconsistent results of the studies may be explained
by differences in patient selection, time elapsed between
SAH and endocrine evaluation, and different methodology
of endocrine tests and definitions of hypopituitarism be-
tween the studies. Some studies were cross-sectional or
retrospective studies [17,33-37,57] which are likely to be
affected by selection bias, misclassification or information
bias. Prospective cohort studies are best qualified in deter-
mining the occurrence of hypopituitarism after SAH. Pa-
tient selection may still be a problem in these studies
[32,37,38]. There were large differences in time elapsed
between SAH and the evaluation of endocrine function
after SAH between studies [34,35,37,38] and even within
studies [34-36]. The association between SAH and hypo-
pituitarism could be affected by the time elapsed between
SAH and the laboratory testing.
Another concern is the definition of hypopituitarism and
methods used to measure endocrine function. In clinical
practice and in clinical research it is difficult to define and
operationalize hypopituitarism. Specific endocrine testing
for each pituitary function must be performed to set an ac-
curate diagnosis. The evaluation of pituitary function is
preferably done according to an algorithm, which is inter-
preted by an endocrinologist in collaboration with a multi-
disciplinary team responsible for the patient [58]. Basal
concentrations alone are not always distinctive, because of
pulsatile, circadian or situational secretion. This may have
led to misinterpretations of hormone values in some of the
studies [17,34,46]. The assessment of ACTH and GH re-
quires dynamic tests to reliably detect deficiency of thesehormones [19]. Dynamic tests were not performed in three
of the studies [17,34,46] and in some studies the tests con-
ducted even varied within the cohort [33,36,38].
Even when dynamic tests were used validation of some
of the tests such as insulin tolerance test, thyrotropin re-
leasing hormone and adrenocorticotropic hormone stimu-
lation test in SAH patients remains a concern [59-62].
Furthermore, the GHRH-arg test is strongly influenced by
body mass index (BMI). Outcomes of GHD should be ad-
justed for BMI, which was not the case in various studies
[32,37,39]. There is a lack of standardized tests, which
makes it difficult to interpret the findings of some studies.
Based on these shortcomings PD after SAH might have
been over-reported in older studies [32].
Despite all shortcomings of the reviewed literature,
there seems to be at least some preliminary evidence
that pituitary dysfunction is associated with SAH. Youn-
ger age was associated with long-term pituitary dysfunc-
tion in one study and hydrocephalus and vasospasm was
associated with pituitary dysfunction in another [34,44].
However, due to the relatively small number of patients
[44] and methodological shortcomings of the studies as
we mentioned earlier (case series with a time range be-
tween 1 and 10 years without pre-trial registry and no
dynamic tests) [34], the role of these factors remains un-
clear. Still there are a few studies with a proper meth-
odological set up and implementation but the number of
cases remains small and the studies show widely diver-
ging results [39-41].
In general, patients with hypopituitarism may have
many different symptoms, including for instance fatigue,
impairment of concentration, infertility, weight gain and
hair loss. For clinicians, it might be efficient to use the
clinical symptoms of hypopituitarism to select patients
for further endocrine evaluation. However the symptoms
are non-specific and do not indicate the presence or type
of endocrine dysfunction accurately. In a study in which
patients were selected for endocrine evaluation based on
clinical symptoms of hypopituitarism [33], the reported
prevalence of pituitary dysfunction was approximately
30%. This is in accordance with other studies, in which
patients were not selected based on symptoms. This sug-
gests that selection based on clinical symptoms is not ef-
ficient. On the other hand there is insufficient evidence
to support routine assessment of pituitary function in all
SAH patients, because the clinical relevance of pituitary
dysfunction after SAH is largely unclear [63].
There were no studies reporting functional long-term
outcome in association with endocrine function after
SAH. In addition, we could not identify any studies that
evaluated the effect of hormone substitution on any of
the clinical symptoms in patients with SAH. Interest-
ingly, there are no proper case–control designed studies
answering the question whether SAH is a risk factor for
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have a case control design and involve a large study popu-
lation, and should therefore probably be based on hospital
registries. Such studies would provide a sound basis for
further scientific explorations of the occurrence and risk
factors for hypopituitarism after SAH.
Conclusions
In conclusion, SAH seems to be associated with increased
risk of endocrine dysfunction. Currently, there are no
neurological or clinical parameters predicting the presence
of hypopituitarism after SAH. Whether detection and pos-
sible treatment of endocrine dysfunction after SAH leads
to better functional recovery is also unknown. Large pro-
spective studies are needed to more precisely assess its ef-
fect on mood, behaviour and quality of life.
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